FDA Issues Warning to Beaute Bounty Over Stem Cells
The agency declared the company's stem cell and placenta products to be unapproved drugs.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Should federal regulators prioritize stricter enforcement against online companies selling unapproved health products?
On September 25, 2026, the FDA issued a warning letter to Beaute Bounty after finding the company markets unapproved biological products. The agency determined these items, including embryonic stem cells, lack necessary licensing for treating conditions like Parkinson's.
Why it matters
The warning clarifies that products containing embryonic stem cells or placental tissue require rigorous clinical verification to ensure safety. Marketing such items without approval poses significant health risks to consumers seeking treatment for serious diseases.
The FDA flagged products including Evgenis Totipotent Embryonic Stem Cells, Laennec, and Melsmon Placenta Japan. These items are marketed for cardiovascular conditions and degenerative diseases without a required biologics license application.
The players
Food and Drug Administration
The federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of drugs, biological products, and medical devices.
Beaute Bounty
This company operates the website beautebountymy.com and markets various stem cell and placenta-based products.
The details
Regulators concluded that these products are not intended for homologous use, classifying them as regulated biological products rather than simple cosmetics or supplements. The agency now requires the firm to submit a written response detailing how it will correct these violations.
Timeline
September 2026: The FDA conducted a review of the company's website.
September 25, 2026: The agency issued an official warning letter to Beaute Bounty.
Within 15 working days: The company must submit a formal written response to the FDA regarding the identified violations.
The Tech Race
This enforcement action follows the established regulatory pattern set by the FDA for all companies marketing biological materials as medical treatments. It highlights the agency's ongoing effort to police the intersection of emerging biotechnological claims and consumer safety standards.
Consumers should be aware that products marketed for serious diseases like Alzheimer's or Parkinson's that lack FDA approval may carry unknown health risks. The agency's intervention aims to prevent the sale of unverified biological treatments that have not undergone clinical trials.
The takeaway
The FDA warning serves as a reminder to verify the medical claims of any biological product before use. Consumers are encouraged to consult licensed healthcare providers for safe treatment options rather than relying on unverified internet sales.
Further reading
For more information on current industry oversight, visit the Biotech section.
Source note: This article includes information reported by U.S. Food and Drug Administration.
Live Poll
Should federal regulators prioritize stricter enforcement against online companies selling unapproved health products?
